Orchestra BioMed Holdings, Inc. (OBIO) Stock

About Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. is led by CEO David Hochman, publicly traded since 2020.

Orchestra BioMed Holdings, Inc. (OBIO) stock trades at $5.59 with a market capitalization of $335.99M. The stock is valued at a negative price-to-earnings (P/E) ratio of -6.01, reflecting a net loss over the last twelve months, price-to-book of 12.91, price-to-sales of 11.14. Over the past 52 weeks the stock has ranged between $2.20 and $6.50, and currently trades 14.0% below its 52-week high.

On profitability, Orchestra BioMed Holdings, Inc. generates a return on equity (ROE) of -125.93% (negative, reflecting a net loss), return on capital employed of -56.73%, an operating margin of -157.58%, a net profit margin of -184.60%.

Orchestra BioMed Holdings, Inc. by the numbers, 2020–2025

Between 2020 and 2025 Orchestra BioMed Holdings, Inc. reported revenue of $6.0M rising to $33.0M, a change of +450.0% across 6 years. Compounded, revenue has grown 40.6% a year over five years, 102.1% over three, 1000.0% over the last twelve months. Net profit fell to $-53.0M.

Operating margin went from -328.8% in 2020 to -154.7% in 2025, a gain of 174.1 percentage points. The most recent net margin is -184.60%. On a trailing twelve-month basis to Jun '26, revenue is $32.0M and net profit $-60.0M.

Borrowings rose from $9.0M to $16.0M, cash from operations was $-49.0M in the latest year, positive in 0 of the last 6.

Return on equity has averaged -74.6% over five years, and was -84.1% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Orchestra BioMed Holdings, Inc. (OBIO) — frequently asked questions